Akebia Therapeutics, Inc. (NASDAQ:AKBA)‘s stock had its “outperform” rating reiterated by stock analysts at Royal Bank Of Canada in a research note issued on Saturday. They presently have a $28.00 price objective on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price target points to a potential upside of 61.85% from the stock’s previous close.

AKBA has been the topic of a number of other reports. Zacks Investment Research raised Akebia Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a research note on Monday, August 14th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of Akebia Therapeutics in a research note on Tuesday, June 6th. BidaskClub lowered Akebia Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 19th. Aegis reaffirmed a “buy” rating on shares of Akebia Therapeutics in a research note on Friday, June 30th. Finally, ValuEngine raised Akebia Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $21.25.

Shares of Akebia Therapeutics (NASDAQ AKBA) opened at 17.30 on Friday. The stock’s 50 day moving average price is $15.33 and its 200 day moving average price is $12.94. The stock’s market capitalization is $316.59 million. Akebia Therapeutics has a one year low of $7.16 and a one year high of $17.79.

Akebia Therapeutics (NASDAQ:AKBA) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.89) by $0.36. The firm had revenue of $28.52 million during the quarter, compared to analyst estimates of $26.50 million. Equities research analysts predict that Akebia Therapeutics will post ($2.68) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Royal Bank Of Canada Reiterates Outperform Rating for Akebia Therapeutics, Inc. (AKBA)” was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/16/royal-bank-of-canada-reiterates-outperform-rating-for-akebia-therapeutics-inc-akba.html.

In related news, Director Muneer A. Satter acquired 1,034,482 shares of Akebia Therapeutics stock in a transaction that occurred on Wednesday, July 5th. The shares were purchased at an average price of $14.50 per share, for a total transaction of $14,999,989.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michel Dahan sold 5,000 shares of Akebia Therapeutics stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $15.00, for a total value of $75,000.00. Following the transaction, the senior vice president now owns 102,224 shares in the company, valued at approximately $1,533,360. The disclosure for this sale can be found here. In the last quarter, insiders have sold 7,544 shares of company stock worth $111,287. 7.95% of the stock is currently owned by company insiders.

A number of institutional investors have recently made changes to their positions in AKBA. RA Capital Management LLC purchased a new position in Akebia Therapeutics during the second quarter worth approximately $12,018,000. Farallon Capital Management LLC purchased a new position in Akebia Therapeutics during the second quarter worth approximately $10,490,000. Marshall Wace North America L.P. purchased a new position in Akebia Therapeutics during the first quarter worth approximately $6,232,000. MARSHALL WACE ASIA Ltd purchased a new position in Akebia Therapeutics during the first quarter worth approximately $6,232,000. Finally, Renaissance Technologies LLC lifted its position in Akebia Therapeutics by 165.4% during the second quarter. Renaissance Technologies LLC now owns 1,025,300 shares of the biopharmaceutical company’s stock worth $14,734,000 after buying an additional 639,033 shares in the last quarter. Hedge funds and other institutional investors own 57.62% of the company’s stock.

About Akebia Therapeutics

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Analyst Recommendations for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.